Sonoma Pharmaceuticals, Inc. (SNOA)
NASDAQ: SNOA · Real-Time Price · USD
2.870
0.00 (0.00%)
At close: Jun 27, 2025, 4:00 PM
2.850
-0.020 (-0.70%)
After-hours: Jun 27, 2025, 4:56 PM EDT
Sonoma Pharmaceuticals Revenue
In the fiscal year ending March 31, 2025, Sonoma Pharmaceuticals had annual revenue of $14.29M with 12.19% growth. Sonoma Pharmaceuticals had revenue of $3.75M in the quarter ending March 31, 2025, with 9.16% growth.
Revenue (ttm)
$14.29M
Revenue Growth
+12.19%
P/S Ratio
0.25
Revenue / Employee
$1,428,800
Employees
8
Market Cap
4.71M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 14.29M | 1.55M | 12.19% |
| Mar 31, 2024 | 12.74M | -537.00K | -4.05% |
| Mar 31, 2023 | 13.27M | 644.00K | 5.10% |
| Mar 31, 2022 | 12.63M | -6.00M | -32.21% |
| Mar 31, 2021 | 18.63M | 701.00K | 3.91% |
| Mar 31, 2020 | Pro | Pro | Pro |
| Mar 31, 2019 | Pro | Pro | Pro |
| Mar 31, 2018 | Pro | Pro | Pro |
| Mar 31, 2017 | Pro | Pro | Pro |
| Mar 31, 2016 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 63.92B |
| AbbVie | 57.37B |
| AstraZeneca | 54.98B |
| Novartis AG | 53.22B |
| Eli Lilly and Company | 49.00B |
| Novo Nordisk | 43.92B |
SNOA News
- 10 days ago - Sonoma Pharmaceuticals Reports Fiscal Year and Fourth Quarter 2025 Financial Results - Accesswire
- 2 months ago - Sonoma Pharmaceuticals Announces Registration of Acne Products in the United Kingdom and Launch of the Products in Leading U.K. Pharmacy Chain - Accesswire
- 3 months ago - Sonoma Pharmaceuticals Secures Extensive U.K. Regulatory Clearances of Key Wound Care and Dermatology Products by the Medicines & Healthcare Products Regulatory Agency (MHRA) - Accesswire
- 4 months ago - Sonoma Pharmaceuticals to Exhibit at 2025 American Academy of Dermatology Annual Meeting in Orlando - Accesswire
- 5 months ago - Sonoma Pharmaceuticals Reports Third Fiscal Quarter 2025 Financial Results - Accesswire
- 7 months ago - Sonoma Pharmaceuticals Successfully Transitions First Products to New EU MDR Requirements for Class IIb Medical Devices - Accesswire
- 7 months ago - Sonoma Pharmaceuticals Announces Relaunch of Prescription Dermatology and Eye Care Product Lines in the United States - Accesswire
- 8 months ago - Sonoma Pharmaceuticals Receives New FDA 510(k) Clearance for Microcyn(R)-based Wound Care Hydrogel - Accesswire